Exploring the landscape of novel targets & pathways in immuno-oncology
December 04, 2023
Lauren Coyle, Editor, Immuno-Oncology Insights, speaks to Yvonne McGrath, Chief Scientific Officer, iTeos Therapeutics, about the current and emerging novel targets and pathways for the use of cancer therapy in the I-O field with a focus on small molecules and antibody targets.
Could you briefly describe your past experiences in cancer research and your current role at iTeos Therapeutics?
Could you give background on the novel targets and pathways development platform at iTeos? How do these represent an advance on previous work?
Can you tell me more about the research and development pipeline that this work fuels?
There's been an increased interest surrounding personalized medicine, do you think this will help with the development of personalized medicine?
What impact is being made by small-molecule targets and do you see any specific areas that require more focus?
Is there any progress in antibody targets, and how can they be further developed?
What challenges are currently facing the I-O field in terms of targeted therapies and how could these be addressed?
Finally, what are some key goals and priorities for your role and iTeos as a whole in the future?